Eye examination with optometrist and patient.

Pioneering Vision Through the SCOTS 2 Study

The Stem Cell Ophthalmology Treatment Study 2 (SCOTS 2) is the largest independent clinical study in the world focusing on the application of cellular therapy for the eye. At MD Stem Cells, we offer patients a specialized pathway for treating degenerative conditions using autologous bone-marrow–derived stem cells.

Our approach is built on "Informed Hope"—providing a scientifically grounded opportunity for patients where traditional standard-of-care treatments may no longer be effective.

Conditions Supported by SCOTS 2

We provide stem cell treatment for eye disease within a clinical framework for a wide range of retinal and optic nerve conditions, including:

Retinal Diseases:
Age-Related Macular Degeneration (AMD), Retinitis Pigmentosa, Stargardt Disease, and Diabetic Retinopathy.
Optic Nerve Disorders: Glaucoma, Optic Nerve Atrophy, and Leber’s Hereditary Optic Neuropathy (LHON).
Ischemic & Hereditary Conditions: Non-Arteritic Ischemic Optic Neuropathy (NAION) and other degenerative retinal dystrophies.

Doctor explaining with heart model to patient.

How the Treatment Works: The Science of Regeneration

Our protocols focus on retinal regeneration and neuroprotection by utilizing the patient’s own stem cells. This autologous method ensures maximum biocompatibility and patient safety.

The Procedure Overview

Aspiration

A small amount of bone marrow is collected from the patient's hip in a minimally invasive procedure.

Concentration

Using FDA-cleared processing systems, the marrow is concentrated to isolate the potent regenerative cells.

Targeted Delivery

Based on the specific diagnosis, cells are delivered through specialized routes-such as intravenous (IV), retrobulbar, or sub-Tenon injections-to ensure the cells reach the areas of the eye requiring repair.

Clinical Insights and Documented Outcomes

At MD Stem Cells, our work is backed by scientific documentation rather than anecdotes. Findings from our studies have been featured in peer-reviewed medical journals, showing the potential for:

Improvements in visual acuity (clarity).
Expansion or stabilization of visual fields.
Enhanced quality of life for study participants.

Investigational Note: As a clinical study, these outcomes are documented for research purposes. All treatments are investigational, and individual results vary.

Why Patients Choose MD Stem Cells

Medical Leadership

Directed by world-renowned experts in regenerative ophthalmology.

Proven Experience

Over a decade of specialized experience in bone-marrow-derived cellular protocols.

Clinical Rigor

Participation in an NIH-registered study ensures the highest standards of data collection and patient transparency.

Safety First

By using your own cells, we eliminate the risk of rejection or complications from donor material.

The Patient Journey: A 3-Day Process

We prioritize clarity and support for our patients throughout the entire experience.

Evaluation

Our team reviews your recent ophthalmic imaging (such as OCT or Visual Fields) to determine eligibility.

Procedure

A single-day clinical procedure directed by board-certified physicians.

Follow-Up

We coordinate with your local ophthalmologist to monitor your progress and contribute to the study data.

Begin Your Eligibility Review

If you have a documented diagnosis and are seeking new options for your vision, we invite you to take the first step. Our team will review your records to see if you qualify for enrollment in the SCOTS 2 study.

Start Your Eligibility Review

Clinical Study Medical Disclaimer

Medical Disclaimer: Stem cell treatments offered through SCOTS 2 are investigational and conducted within NIH-registered clinical studies. These treatments are not FDA-approved standard of care. Outcomes vary and are not guaranteed.

Comprehensive Retinal Regeneration Protocol For Advanced Vision Support

Our eye condition solutions encompass a sophisticated treatment protocol designed specifically for patients experiencing progressive vision decline due to retinal and optic nerve disorders. The SCOTS 2 study utilizes autologous stem cell therapy derived from your own bone marrow, ensuring compatibility and minimizing adverse reactions while maximizing therapeutic potential. We address multiple degenerative eye conditions within our clinical study framework. Patients with age-related macular degeneration benefit from our retinal regeneration treatment approach, while those with glaucoma receive specialized stem cell therapy for optic neuropathy. Our protocol also supports individuals with diabetic retinopathy, providing treatment for retinitis pigmentosa using stem cells, and offers hope for patients with Stargardt disease through our comprehensive clinical study approach. We maintain comprehensive documentation throughout the treatment process, ensuring each participant receives personalized attention from our experienced ophthalmology specialists.

Our Care Commitment

Discover how our NIH-registered SCOTS 2 study brings innovative stem cell therapy options for degenerative eye diseases. Reach out to our specialists today.

Contact Our Team